Self-expanding metal stents for biliary drainage in patients with resectable pancreatic cancer

Single-center experience with 79 cases

Ashwani K. Singal, William A. Ross, Praveen Guturu, Gauri R. Varadhachary, Milind Javle, Sathya R. Jaganmohan, Ramu P. Raju, Jason B. Fleming, Gottumukala S. Raju, Yong Fang Kuo, Jeffrey H. Lee

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background and Aims To study pre-operative and perioperative course and outcome on follow up after pancreaticoduodenenctomy (PD) for resectable pancreatic cancer amongst patients receiving self-expanding metal stents (SEMS). Methods Medical charts of consecutively reviewed patients (2005-2009) with resectable pancreatic cancer and SEMS placement before PD at the MD Anderson Cancer Center (MDACC) were studied. Results Seventy-nine patients (mean age, 68 ± 9 years; 54% males) undergoing PD after SEMS placement were analyzed. Of these, 70% (55/79) had come with previous plastic stents placed within a median of 29 (5-216) days because of presentation and most (95%) underwent neoadjuvant chemoradiation after SEMS placement. The median interval between SEMS placement and PD was 120 (range 28-306) days. There were no technical difficulties during PD. The resected tumor was stage T3 in 72 patients, positive node in 44, lymphovascular invasion in 47, and perineural invasion in 62. Within 30 days after surgery, 26 (33%) patients developed complications requiring intervention, but none died. During a median follow-up of 349 (14-1,508) days after surgery, 32 (41%) patients developed metastatic disease, and 20 (25%) died; median survival was approximately 3 years. Development of metastatic disease during follow-up independently predicted survival with hazard ratio of 16 (95% CI: 4-68; P = 0.0001). Conclusions Contrary to the tendency of avoiding the use of metal stents for biliary decompression amongst patients with resectable pancreatic cancer, our study demonstrated that SEMS did not adversely affect surgical technique, postoperative course, or long-term outcome. Therefore, metal stents should be considered for patients with resectable pancreatic cancer who will undergo preoperative chemoradiation.

Original languageEnglish (US)
Pages (from-to)3678-3684
Number of pages7
JournalDigestive Diseases and Sciences
Volume56
Issue number12
DOIs
StatePublished - Dec 2011

Fingerprint

Pancreatic Neoplasms
Stents
Drainage
Metals
Ambulatory Surgical Procedures
Survival
Decompression
Plastics
Neoplasms

Keywords

  • Metal stents
  • Pancreatic cancer
  • Pancreaticoduodenectomy
  • SEMS
  • Whipple

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology

Cite this

Self-expanding metal stents for biliary drainage in patients with resectable pancreatic cancer : Single-center experience with 79 cases. / Singal, Ashwani K.; Ross, William A.; Guturu, Praveen; Varadhachary, Gauri R.; Javle, Milind; Jaganmohan, Sathya R.; Raju, Ramu P.; Fleming, Jason B.; Raju, Gottumukala S.; Kuo, Yong Fang; Lee, Jeffrey H.

In: Digestive Diseases and Sciences, Vol. 56, No. 12, 12.2011, p. 3678-3684.

Research output: Contribution to journalArticle

Singal, AK, Ross, WA, Guturu, P, Varadhachary, GR, Javle, M, Jaganmohan, SR, Raju, RP, Fleming, JB, Raju, GS, Kuo, YF & Lee, JH 2011, 'Self-expanding metal stents for biliary drainage in patients with resectable pancreatic cancer: Single-center experience with 79 cases', Digestive Diseases and Sciences, vol. 56, no. 12, pp. 3678-3684. https://doi.org/10.1007/s10620-011-1815-7
Singal, Ashwani K. ; Ross, William A. ; Guturu, Praveen ; Varadhachary, Gauri R. ; Javle, Milind ; Jaganmohan, Sathya R. ; Raju, Ramu P. ; Fleming, Jason B. ; Raju, Gottumukala S. ; Kuo, Yong Fang ; Lee, Jeffrey H. / Self-expanding metal stents for biliary drainage in patients with resectable pancreatic cancer : Single-center experience with 79 cases. In: Digestive Diseases and Sciences. 2011 ; Vol. 56, No. 12. pp. 3678-3684.
@article{c3053121e0834f6b992d90ccf796f3e0,
title = "Self-expanding metal stents for biliary drainage in patients with resectable pancreatic cancer: Single-center experience with 79 cases",
abstract = "Background and Aims To study pre-operative and perioperative course and outcome on follow up after pancreaticoduodenenctomy (PD) for resectable pancreatic cancer amongst patients receiving self-expanding metal stents (SEMS). Methods Medical charts of consecutively reviewed patients (2005-2009) with resectable pancreatic cancer and SEMS placement before PD at the MD Anderson Cancer Center (MDACC) were studied. Results Seventy-nine patients (mean age, 68 ± 9 years; 54{\%} males) undergoing PD after SEMS placement were analyzed. Of these, 70{\%} (55/79) had come with previous plastic stents placed within a median of 29 (5-216) days because of presentation and most (95{\%}) underwent neoadjuvant chemoradiation after SEMS placement. The median interval between SEMS placement and PD was 120 (range 28-306) days. There were no technical difficulties during PD. The resected tumor was stage T3 in 72 patients, positive node in 44, lymphovascular invasion in 47, and perineural invasion in 62. Within 30 days after surgery, 26 (33{\%}) patients developed complications requiring intervention, but none died. During a median follow-up of 349 (14-1,508) days after surgery, 32 (41{\%}) patients developed metastatic disease, and 20 (25{\%}) died; median survival was approximately 3 years. Development of metastatic disease during follow-up independently predicted survival with hazard ratio of 16 (95{\%} CI: 4-68; P = 0.0001). Conclusions Contrary to the tendency of avoiding the use of metal stents for biliary decompression amongst patients with resectable pancreatic cancer, our study demonstrated that SEMS did not adversely affect surgical technique, postoperative course, or long-term outcome. Therefore, metal stents should be considered for patients with resectable pancreatic cancer who will undergo preoperative chemoradiation.",
keywords = "Metal stents, Pancreatic cancer, Pancreaticoduodenectomy, SEMS, Whipple",
author = "Singal, {Ashwani K.} and Ross, {William A.} and Praveen Guturu and Varadhachary, {Gauri R.} and Milind Javle and Jaganmohan, {Sathya R.} and Raju, {Ramu P.} and Fleming, {Jason B.} and Raju, {Gottumukala S.} and Kuo, {Yong Fang} and Lee, {Jeffrey H.}",
year = "2011",
month = "12",
doi = "10.1007/s10620-011-1815-7",
language = "English (US)",
volume = "56",
pages = "3678--3684",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "12",

}

TY - JOUR

T1 - Self-expanding metal stents for biliary drainage in patients with resectable pancreatic cancer

T2 - Single-center experience with 79 cases

AU - Singal, Ashwani K.

AU - Ross, William A.

AU - Guturu, Praveen

AU - Varadhachary, Gauri R.

AU - Javle, Milind

AU - Jaganmohan, Sathya R.

AU - Raju, Ramu P.

AU - Fleming, Jason B.

AU - Raju, Gottumukala S.

AU - Kuo, Yong Fang

AU - Lee, Jeffrey H.

PY - 2011/12

Y1 - 2011/12

N2 - Background and Aims To study pre-operative and perioperative course and outcome on follow up after pancreaticoduodenenctomy (PD) for resectable pancreatic cancer amongst patients receiving self-expanding metal stents (SEMS). Methods Medical charts of consecutively reviewed patients (2005-2009) with resectable pancreatic cancer and SEMS placement before PD at the MD Anderson Cancer Center (MDACC) were studied. Results Seventy-nine patients (mean age, 68 ± 9 years; 54% males) undergoing PD after SEMS placement were analyzed. Of these, 70% (55/79) had come with previous plastic stents placed within a median of 29 (5-216) days because of presentation and most (95%) underwent neoadjuvant chemoradiation after SEMS placement. The median interval between SEMS placement and PD was 120 (range 28-306) days. There were no technical difficulties during PD. The resected tumor was stage T3 in 72 patients, positive node in 44, lymphovascular invasion in 47, and perineural invasion in 62. Within 30 days after surgery, 26 (33%) patients developed complications requiring intervention, but none died. During a median follow-up of 349 (14-1,508) days after surgery, 32 (41%) patients developed metastatic disease, and 20 (25%) died; median survival was approximately 3 years. Development of metastatic disease during follow-up independently predicted survival with hazard ratio of 16 (95% CI: 4-68; P = 0.0001). Conclusions Contrary to the tendency of avoiding the use of metal stents for biliary decompression amongst patients with resectable pancreatic cancer, our study demonstrated that SEMS did not adversely affect surgical technique, postoperative course, or long-term outcome. Therefore, metal stents should be considered for patients with resectable pancreatic cancer who will undergo preoperative chemoradiation.

AB - Background and Aims To study pre-operative and perioperative course and outcome on follow up after pancreaticoduodenenctomy (PD) for resectable pancreatic cancer amongst patients receiving self-expanding metal stents (SEMS). Methods Medical charts of consecutively reviewed patients (2005-2009) with resectable pancreatic cancer and SEMS placement before PD at the MD Anderson Cancer Center (MDACC) were studied. Results Seventy-nine patients (mean age, 68 ± 9 years; 54% males) undergoing PD after SEMS placement were analyzed. Of these, 70% (55/79) had come with previous plastic stents placed within a median of 29 (5-216) days because of presentation and most (95%) underwent neoadjuvant chemoradiation after SEMS placement. The median interval between SEMS placement and PD was 120 (range 28-306) days. There were no technical difficulties during PD. The resected tumor was stage T3 in 72 patients, positive node in 44, lymphovascular invasion in 47, and perineural invasion in 62. Within 30 days after surgery, 26 (33%) patients developed complications requiring intervention, but none died. During a median follow-up of 349 (14-1,508) days after surgery, 32 (41%) patients developed metastatic disease, and 20 (25%) died; median survival was approximately 3 years. Development of metastatic disease during follow-up independently predicted survival with hazard ratio of 16 (95% CI: 4-68; P = 0.0001). Conclusions Contrary to the tendency of avoiding the use of metal stents for biliary decompression amongst patients with resectable pancreatic cancer, our study demonstrated that SEMS did not adversely affect surgical technique, postoperative course, or long-term outcome. Therefore, metal stents should be considered for patients with resectable pancreatic cancer who will undergo preoperative chemoradiation.

KW - Metal stents

KW - Pancreatic cancer

KW - Pancreaticoduodenectomy

KW - SEMS

KW - Whipple

UR - http://www.scopus.com/inward/record.url?scp=84856198770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856198770&partnerID=8YFLogxK

U2 - 10.1007/s10620-011-1815-7

DO - 10.1007/s10620-011-1815-7

M3 - Article

VL - 56

SP - 3678

EP - 3684

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 12

ER -